Relation of interleukin-6 level with coronary artery disease severity in patients undergoing coronary angiography

Gerin, Fethullah; Durmuş, Erdal; Yaman, Ali; Sünbül, Murat; Mammadov, Ceyhun; Bozbay, Mehmet; Sarı, İbrahim; Kıvrak, Tarık

doi:10.5152/eurjther.2017.01007

Cited by 2 publications

(4 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unsurprisingly, we observed that IL-6 level positively correlates with other inflammatory parameters hsCRP and WBC, which is consistent with the results of other studies [19]. The levels of IL-6 [1,15,37] and hsCRP [38,39] could help predict the angiographic severity of CAD. It is well-known that these inflammatory markers have been linked to coronary events.…”

Section: Discussionsupporting

confidence: 91%

Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease

et al. 2019

View full text Add to dashboard Cite

Background: Over the last two decades, many studies have investigated the association between interleukin 6 (IL-6) and pathogenesis and progression of coronary artery disease (CAD). Patients with CAD manifested at a young age are a particularly interesting group. They differ from older patients, not only in terms of the severity of coronary artery atherosclerosis, but also risk factor profiles, short- and long-term prognosis after myocardial infarction (MI). The role of IL-6 in younger patients with CAD is less well-known. Therefore, our study aimed to analyze the relationship between IL-6 level and other inflammations, atherosclerosis, and cardiac function parameters in early onset CAD patients. Methods: The study covered 100 patients with early onset CAD and a group of 50 healthy participants. Plasma levels of IL-6 and basic biochemical parameters, anthropometric, echocardiographic, and arteries Doppler ultrasound measurements were performed. Results: We did not observe a significant difference in IL-6 concentration in plasma between patients with early onset CAD and a control group, but IL-6 level was negatively correlated with echocardiographic measurements of ascending aorta diameter, left ventricular shortening fraction, and right ventricular end-diastolic diameter in our patients. Conclusions: In patients with early onset CAD, plasma IL-6 level is associated with other inflammation parameters and with cardiac function, potentially contributing to right ventricular remodeling and left ventricular systolic dysfunction. This suggests possible prognostic benefits of long-time observation of IL-6 level after the acute coronary syndrome.

show abstract

Section: Discussionsupporting

confidence: 91%

Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease

et al. 2019

View full text Add to dashboard Cite

show abstract

“…IL-6 is a strong stimulator of hs-CRP liver secretion and a central inflammation mediator in the atherosclerotic process, making it a good candidate for this position. Moreover, the rising number of prospective studies linking IL-6 serum levels to the severity of CAD supports future research on this topic [ 108 , 109 , 110 , 111 , 112 , 113 ].…”

Section: The Potential Use Of Apolipoprotein B and Interleukin-6 As F...mentioning

confidence: 94%

“…IL-6 levels correlated with the two severity scores, and they were higher in the CAD group. Furthermore, after the regression analysis, IL-6 proved to be an independent predictor for the presence of CAD, with serum levels >7.91 pg/mL being able to predict significative atherosclerotic plaques with a sensitivity of 78% and a specificity of over 70% [ 109 ]. Similar results were found in another recent prospective study, which included 1796 patients who underwent computed tomography angiography.…”

Section: Interleukinmentioning

confidence: 99%

“…This could also allow us to reclassify the patients based on the cardiovascular risk. However, at the moment, their sensibility and specificity should still be studied in larger groups, in order to fully understand their mechanisms, what influences their levels, and how exactly they correlate to the atherosclerotic process [ 108 , 109 , 110 , 111 , 112 , 113 ].…”

Section: The Potential Use Of Apolipoprotein B and Interleukin-6 As F...mentioning

confidence: 99%

See 1 more Smart Citation

Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment

Jigoranu,

Roca,

Costache

et al. 2023

Life

View full text Add to dashboard Cite

Atherosclerosis is a significant health concern with a growing incidence worldwide. It is directly linked to an increased cardiovascular risk and to major adverse cardiovascular events, such as acute coronary syndromes. In this review, we try to assess the potential diagnostic role of biomarkers in the early identification of patients susceptible to the development of atherosclerosis and other adverse cardiovascular events. We have collected publications concerning already established parameters, such as low-density lipoprotein cholesterol (LDL-C), as well as newer markers, e.g., apolipoprotein B (apoB) and the ratio between apoB and apoA. Additionally, given the inflammatory nature of the development of atherosclerosis, high-sensitivity c-reactive protein (hs-CRP) or interleukin-6 (IL-6) are also discussed. Additionally, newer publications on other emerging components linked to atherosclerosis were considered in the context of patient evaluation. Apart from the already in-use markers (e.g., LDL-C), emerging research highlights the potential of newer molecules in optimizing the diagnosis of atherosclerotic disease in earlier stages. After further studies, they might be fully implemented in the screening protocols.

show abstract

Relation of interleukin-6 level with coronary artery disease severity in patients undergoing coronary angiography

Cited by 2 publications

References 12 publications

Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease

Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease

Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment

Contact Info

Product

Resources

About